In our cirrhosis studies, we are working to learn if our exploratory technology can help individuals who have been diagnosed with cirrhosis-related ascites (fluid that builds up inside the abdomen)
to be more comfortable, to require fewer or less frequent medical procedures to drain ascites fluid, and to see if the treatment can help people with ascites to live outside of the hospital for longer periods of time.

BioVie is currently investigating BIV201, a novel formulation of terlipressin, in human clinical trials. In BioVie’s studies of BIV201, the exploratory medication is provided as a continuous infusion formulation delivered by a small, portable pump that the user can wear while engaging in typical tasks and activities at home.

BioVie believes that BIV201 may have the potential to slow the build-up of ascites fluid in the abdomen, and that it may do so by constricting certain blood vessels, potentially contributing
to improved blood flow in the kidneys and liver. This expected improvement may allow biological systems within the body to respond differently in the presence of BIV201, reducing the production of ascites fluid, and lessening the “fluid in the belly” associated with cirrhosis.